Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy

被引:31
|
作者
Chow, Vincent [1 ,2 ,3 ]
Reddel, Caroline [1 ,2 ,3 ]
Pennings, Gabrielle [1 ,2 ,3 ]
Scott, Elizabeth [4 ]
Pasqualon, Tundra [5 ]
Ng, Austin C. C. [2 ,3 ]
Yeoh, Thomas [2 ]
Curnow, Jennifer [1 ,3 ,6 ]
Kritharides, Leonard [1 ,2 ,3 ]
机构
[1] ANZAC Res Inst, Sydney, NSW, Australia
[2] Concord Repatriat Gen Hosp, Dept Cardiol, Sydney Local Hlth Dist, Concord, NSW 2139, Australia
[3] Univ Sydney, Sydney, NSW 2006, Australia
[4] Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2006, Australia
[5] Croydon Hlth Ctr, Dept Psychiat, Sydney, NSW, Australia
[6] Concord Repatriat Gen Hosp, Dept Haematol, Sydney Local Hlth Dist, Concord, NSW 2139, Australia
基金
英国医学研究理事会;
关键词
Schizophrenia; Blood coagulation test; Coagulation; Thrombosis; Fibrinolysis; HIGH-DENSITY-LIPOPROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; RISK-FACTOR; PULMONARY-EMBOLISM; PLASMA-LEVELS; PROTEIN-S; UNMEDICATED PATIENTS; LABORATORY METHOD;
D O I
10.1016/j.schres.2014.12.042
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Patients with schizophrenia are at increased risk of venous thromboembolism. The mechanisms underlying this association are poorly understood. Aims: We investigated whether there is a global hypercoagulable state in patientswith schizophrenia utilising the overall haemostatic potential (OHP) assay which assesses overall coagulation potential (OCP), haemostatic potential (OHP) and fibrinolytic potential (OFP). Method: Citrated plasma was collected for OHP assays from patients with schizophrenia on long-term antipsychotic treatment and compared with healthy age-and sex-matched controls. Time courses of fibrin formation and degradation were measured by spectrophotometry (absorption of 405 nm) after the addition of tissue factor and tissue plasminogen activator to plasma. Results: Ninety patients with schizophrenia (antipsychotic treatment-15.9 +/- 9.7 years) and 30 controls were recruited. Patients with schizophrenia had higher rates of smoking and levels of inflammatory markers (high-sensitivity C-reactive protein and neutrophil-to-lymphocyte ratio) than controls. Whilst D-dimer, fibrinogen and platelet count did not differ between patients with schizophrenia and controls, the OCP (54.0 +/- 12.6 vs 45.9 +/- 9.1, p = 0.002) and OHP (12.6 +/- 5.8 vs 7.2 +/- 3.7, p < 0.001) were higher, and OFP was lower (76.6 +/- 9.8% vs 84.9 +/- 6.4%, p < 0.001) in patients with schizophrenia, implying both a hypercoagulable and hypofibrinolytic state in these patients. Importantly, abnormalities in overall coagulation were independently predicted by levels of plasminogen-activator-inhibitor-1, fibrinogen, platelet count, inflammatory markers and plasma triglycerides, suggesting a multifactorial aetiology. Conclusion: Patients with schizophrenia have evidence of a global hypercoagulable and hypofibrinolytic state which may contribute to their increased risk of venous thromboembolism. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [1] Long-term combination antipsychotic treatment in VA patients with schizophrenia
    Kreyenbuhl, Julie
    Valenstein, Marcia
    McCarthy, John F.
    Ganoczy, Dara
    Blow, Frederic C.
    [J]. SCHIZOPHRENIA RESEARCH, 2006, 84 (01) : 90 - 99
  • [2] Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic
    Kitajima, Rei
    Miyamoto, Seiya
    Tenjin, Tomomi
    Ojima, Kazuaki
    Ogino, Shin
    Miyake, Nobumi
    Fujiwara, Keisuke
    Funamoto, Yasuyuki
    Arai, Jun
    Tsukahara, Sachiko
    Ito, Yukie
    Tadokoro, Masanori
    Anai, Kiriko
    Kaneda, Yasuhiro
    Yamaguchi, Noboru
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 36 (02): : 300 - 306
  • [3] Long-term studies of antipsychotic drugs in schizophrenia
    Lewander, T
    [J]. EUROPEAN PSYCHIATRY, 1996, 11 (03) : 127 - 134
  • [4] Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic
    Kitajima, R.
    Miyamoto, S.
    Tenjin, T.
    Ojima, K.
    Ogino, S.
    Miyake, N.
    Fujiwara, K.
    Kaneda, Y.
    Yamaguchi, N.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 120 - 121
  • [5] Long-term effects of discontinuing antipsychotic medication in patients with chronic schizophrenia
    Wyatt, RJ
    Henter, I
    [J]. SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 302 - 303
  • [6] VACCINATION OF PATIENTS RECEIVING LONG-TERM CORTICOSTEROID THERAPY
    BRANDON, ML
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 207 (09): : 1724 - &
  • [7] Care of patients receiving long-term anticoagulant therapy
    Schulman, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 675 - 683
  • [8] Atypical antipsychotic drugs and long-term outcome in schizophrenia
    Weiden, P
    Aquila, R
    Standard, J
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 : 53 - 60
  • [9] Long-term studies of antipsychotic drugs in schizophrenia - Discussion
    Moller, HJ
    [J]. EUROPEAN PSYCHIATRY, 1996, 11 (03) : 135 - 136
  • [10] Long-term antipsychotic treatment in patients with schizophrenia: the gap between research and practice
    Stuhec, M.
    [J]. EUROPEAN PSYCHIATRY, 2020, 63 : S609 - S609